Now I have all the information I need to produce the consolidated review. Let me carefully cross-check each claim and construct the final evaluation.

---

## Summary

This paper introduces SUFO, a systematic framework combining Supervised probing, Unsupervised similarity analysis (RSA), Feature dynamics (PCA-based cluster analysis), and Outlier analysis to interpret fine-tuned transformer feature spaces. In a case study on pathology report classification with five 110M-parameter models spanning general, mixed, and domain-specific pre-training, the paper reports three main findings: (1) domain-specific PubMedBERT has the most useful pre-trained features but overfits to minority classes under imbalance, while mixed-domain models resist overfitting; (2) in-domain pre-training accelerates feature disambiguation during fine-tuning; and (3) fine-tuned feature spaces exhibit extreme sparsification, enabling clinically meaningful outlier detection.

---

## Strengths

- **Empirical discovery about pre-training data and overfitting validated on two datasets.** The paper demonstrates that PubMedBERT, despite having the best pre-trained features (highest probing average), suffers from severe overfitting to minority classes after fine-tuning under class imbalance (Path-PG: F1=0.770 vs. Clinical BioBERT: 0.959). This finding is **replicated on MedNLI** with simulated imbalances (lines 92–93: "Clinical BioBERT outperforms PubMedBERT in the Highly Imbalanced set... corroborating our finding on the pathology reports"), strengthening the claim beyond a single task. This is a non-obvious, practically relevant insight for practitioners choosing clinical models.

- **Integration of complementary analysis techniques yields richer diagnostics than any single method.** SUFO combines probing (what information is present pre-fine-tuning), RSA (how features change), feature dynamics (when disambiguation occurs), and outlier analysis (what failure modes emerge). The components are individually established, but the integrated pipeline—applied systematically across five models on real clinical data with expert validation—provides a template for diagnosing fine-tuned models that is greater than the sum of its parts.

- **Striking finding about extreme feature sparsification enabling interpretable outlier analysis.** The paper shows that the first two PCs of fine-tuned [CLS] features explain ~95% of variance for all models and tasks. This sparsity is leveraged to extract outliers via 2D clustering, and a domain expert classifies these into clinically meaningful categories (wrong labels, inconsistent reports, truncated reports, boundary cases). The finding that domain-specific models detect more "missing information" outliers than general-domain models is a concrete, interpretable result with practical implications for model auditing.

---

## Weaknesses

### Fatal
None.

### Major
None that threaten the paper's core claims. The main findings are supported by evidence across two datasets and are not undermined by the weaknesses below.

### Minor

- **Feature disambiguation timing claim rests on visual inspection without quantitative validation.** The paper states that in-domain models disambiguate around epoch 6 while general-domain models do so around epoch 9 (line 173), but this is based on visual assessment of PCA scatterplots. No quantitative metric (silhouette score, cluster purity, centroid distance, or mutual information) is used to measure disambiguation across checkpoints or models. While the qualitative analysis is informative, the specific timing claim would be strengthened by a reproducible statistic.

- **High variance on Path-PG for some models without statistical testing.** PubMedBERT's Path-PG F1 has std=0.12 across 3 runs, and BERT/TNLR have std=0.16/0.18. The gap between PubMedBERT (0.770) and Clinical BioBERT (0.959) is large, and the MedNLI replication partially mitigates this concern, but a permutation test or confidence intervals would increase confidence that the overfitting pattern is not a fluke of high-variance runs.

- **Supervised probing results show only marginal differences between models.** The F1 averages in Table 2 cluster tightly: PubMedBERT (0.494), BERT (0.493), Clinical BioBERT (0.487), BioBERT (0.477). The gap of 0.001 between PubMedBERT and BERT is negligible relative to standard deviations. The paper's claim that PubMedBERT "contains the most useful information" is technically correct but overstated—the probing evidence for domain-specific advantage is weak.

- **Single-expert validation with no inter-rater reliability.** The outlier evaluation (Section 5.2) relies on one clinician's judgment. While this is common practice in clinical NLP and does not invalidate the results, the taxonomy of outlier modes would be more robust with at least two annotators and a reported agreement metric (e.g., Cohen's κ).

### Trivial

- **The PC probing experiment (Section 5.1) is mentioned qualitatively ("surge in performance after adding back first 2 PCs") but no figure or table is shown.** This would be a natural place for a quantitative result.
- **RSA analysis (Section 4.1) reports observations as qualitative (e.g., "moderate reconfiguration") without confidence intervals or bootstrapped standard errors.** Differences between models from visual inspection of RSA curves would be more convincing with uncertainty quantification.

---

## Nice-to-Haves

- **Comparison to simpler interpretability methods.** SUFO is a diagnostic framework, not a replacement for local explanation methods like LIME/SHAP, but the paper would be strengthened by showing whether SUFO's insights (e.g., outlier modes) overlap with or complement what attention analysis or gradient-based methods would surface.
- **Robustness analysis of the outlier clustering method.** Varying the number of 1D intervals, distance metrics, or PC rank used would assess whether the outlier labels are stable. A single ad-hoc clustering approach is sufficient for an initial study but sensitivity analysis would strengthen the claims.
- **Concrete outlier examples.** Showing actual (de-identified) pathology report excerpts for each outlier mode alongside model predictions and expert comments would make the outlier analysis more actionable for clinicians.

---

## Removed Points

- **"Central claim supported by only a single task"** — Factually incorrect. The paper validates the overfitting finding on MedNLI (line 92–93): "Clinical BioBERT outperforms PubMedBERT in the Highly Imbalanced set... corroborating our finding on the pathology reports." The finding is supported by two datasets, not one.
- **"Outlier distribution table (gen_outlier) is missing"** — This table (Table~\ref{tab:gen_outlier}) and the outlier types table (Table~\ref{tab:outlier_types}) are in the appendix, which is stripped by the PDF parser. These exist in the original submission.
- **"SUFO is not compared to LIME/SHAP/TCAV"** — SUFO is a feature-space diagnostic framework, not a competing instance-level explanation method. The paper does not claim to outperform LIME/SHAP. Criticizing its absence is scope creep.
- **Pure formatting/style nitpicks and claims about "convoluted" language in the clustering description** — The clustering algorithm is described precisely with mathematical notation (line 229); it may require careful reading but is not convoluted.
- **Claim about "missing related works"** — Cannot be confirmed without external sources.

---

## Novel Insights

Beyond the paper's own contributions, the reviews surface one noteworthy observation: the probing results (Table 2) suggest that the amount of task-relevant information in pre-trained features is nearly indistinguishable across BERT, BioBERT, Clinical BioBERT, and PubMedBERT (averages: 0.493, 0.477, 0.487, 0.494). This implies that the dramatic performance differences after fine-tuning (especially on Path-PG) stem not from what information is *present* in pre-trained features, but from how fine-tuning *distorts* those features differently across models. The paper's RSA and feature dynamics analyses partially address this mechanism, but the probing results themselves—showing near-equality—highlight that the real action is in the fine-tuning dynamics, not the pre-trained representations. This reframes the problem: rather than asking "which model has better features?", the community might ask "which model's features are more robustly updated during fine-tuning under imbalance?"

---

## Suggestions

1. **Add a quantitative metric for feature disambiguation** (silhouette score or cluster purity per epoch/layer) to replace or supplement the visual PCA inspection. This would make the "faster disambiguation" claim reproducible and measurable.
2. **Report bootstrapped confidence intervals or permutation tests** for the key Path-PG fine-tuning results (Table 1), to establish statistical significance despite the high variance.
3. **Include the missing appendix tables** (gen_outlier and outlier_types) in the main paper or supplement, as they are essential for verifying the outlier analysis claims.
4. **Tone down the claim about probing** — the 0.001 F1 gap between PubMedBERT and BERT in Table 2 does not support strong conclusions about domain-specific pre-training providing "more useful information."
5. **Add a second annotator** for the outlier evaluation (or acknowledge this limitation more prominently) to improve the reliability of the outlier taxonomy.

---

## Score and Decision

The paper tackles a practically important problem with a sensible methodology. The core finding—that domain-specific pre-training can hurt under class imbalance, while mixed-domain training confers robustness—is non-obvious, empirically demonstrated, and validated on a second dataset. The SUFO framework is a useful integration of existing techniques that collectively provide richer diagnostics than any component alone. The weaknesses (qualitative timing claims, high variance without significance tests, marginal probing differences, single-expert validation) are real but addressable and do not invalidate the core contributions. The paper would benefit from the suggested revisions but is already a solid contribution to clinical NLP interpretability.

**Originality:** Good — the finding about domain-specific overfitting is genuinely interesting and counterintuitive.  
**Importance of question:** High — understanding when fine-tuned clinical models fail is critical for safe deployment.  
**Claims supported:** Partially — the main claim is supported, but the feature disambiguation timing claim lacks quantitative evidence.  
**Soundness of experiments:** Adequate but could be improved with statistical tests and a second annotator.  
**Clarity of writing:** Clear, well-structured, though the appendix stripping affects readability of some claims.  
**Value to community:** The SUFO pipeline and the empirical findings offer practical guidance for model selection and auditing in clinical NLP.

MY FINAL SCORE: <pineapple>6.0</pineapple>
MY FINAL DECISION: <orange>Accept</orange>